Rapid reduction of substantially increased myoglobin and creatine kinase levels using a hemoadsorption device (CytoSorb®)—A case report
Erich Moresco, Christopher Rugg, Mathias Ströhle and 1 more
Clinical Case Reports · 2022
doi:10.1002/ccr3.5272 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Abstract Rhabdomyolysis (RM) is a potentially life‐threatening entity that can lead to acute kidney injury (AKI). Continuous renal replacement therapy (CRRT) alone is known as effective therapy, but the additional use of a hemoadsorber (like CytoSorb®) might increase its efficacy.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.